Rasilez News
Most Popular Rasilez Story
Blockbuster hopes for Rasilez fade at Novartis
Novartis' ($NVS) bid to expand the use of Rasilez has run into serious trouble. The pharma company joined the lineup of Big Pharma companies reporting trial setbacks today with the news that Read more...
Latest Headlines
- December 20, 2011
- November 28, 2011
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
